Sugi Predict

Sugi Predict / Targets / KDR

KDR

Vascular endothelial growth factor receptor 2 · P35968 · KDR on Sugi Atlas →

747,514 patent compounds predicted against KDR, 462,535 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vatalanib Vatalanib (SCHEMBL18286) 1.00 19/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 16/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 16/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 16/20
SCHEMBL12162 SCHEMBL12162 0.74 15/20
SCHEMBL10811 SCHEMBL10811 0.57 15/20
SCHEMBL20010 SCHEMBL20010 0.52 15/20
SCHEMBL9280 SCHEMBL9280 0.77 14/20
SCHEMBL9010 SCHEMBL9010 0.54 14/20
Vandetanib Vandetanib (SCHEMBL9044) 1.00 13/20
SCHEMBL11517 SCHEMBL11517 0.84 13/20
SCHEMBL11807 SCHEMBL11807 0.59 13/20
Bilirubin Bilirubin (SCHEMBL19065) 0.38 13/20
SCHEMBL8684 SCHEMBL8684 0.82 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL8436) 0.68 12/20
SCHEMBL41746 SCHEMBL41746 0.67 12/20
SCHEMBL12282 SCHEMBL12282 0.59 12/20
SCHEMBL12366 SCHEMBL12366 0.67 11/20
SCHEMBL11830 SCHEMBL11830 0.48 11/20
Whi-P131 Whi-P131 (SCHEMBL29295) 1.00 10/20

Clinical trials — most relevant to KDR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma PHASE3COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M PHASE2COMPLETED
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib PHASE1/PHASE2COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer PHASE2COMPLETED
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma PHASE2COMPLETED
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer PHASE2UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients PHASE2UNKNOWN
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites PHASE1/PHASE2RECRUITING
High-dose Bevacizumab in Advanced Renal Carcinoma Patients PHASE2COMPLETED
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment PHASE2COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma PHASE1/PHASE2UNKNOWN
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer PHASE2COMPLETED
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors PHASE1WITHDRAWN
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) PHASE1COMPLETED
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function PHASE1COMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis nanCOMPLETED
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial nanUNKNOWN
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece nanCOMPLETED
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis nanUNKNOWN
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain nanRECRUITING
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDR binder may also engage these)

ProteinNameSimilarity
P52583 — 1.000 P52583 →
Q5GIT4 — 1.000 Q5GIT4 →
O08775 — 1.000 O08775 →
P35918 — 1.000 P35918 →
P79701 — 1.000 P79701 →
Q5MD89 — 1.000 Q5MD89 →
P26619 — 1.000 P26619 →
Q8JFR5 — 1.000 Q8JFR5 →
Q9I8N6 — 1.000 Q9I8N6 →
P43481 — 1.000 P43481 →
Q76II0 — 1.000 Q76II0 →
Q2HWD6 — 1.000 Q2HWD6 →
Q00495 — 1.000 Q00495 →
Q28889 — 1.000 Q28889 →
Q28317 — 1.000 Q28317 →
Q8AXB3 — 1.000 Q8AXB3 →
Q8AXC7 — 1.000 Q8AXC7 →
FLT1 Vascular endothelial growth factor receptor 1 1.000 landscape →
P53767 — 0.999 P53767 →
Q91909 — 0.999 Q91909 →
P26618 — 0.999 P26618 →
PDGFRA Platelet-derived growth factor receptor alpha 0.999 landscape →
P05532 — 0.999 P05532 →
Q8QHL3 — 0.998 Q8QHL3 →
Q08156 — 0.998 Q08156 →
Q9PUF6 — 0.998 Q9PUF6 →
Q91ZT1 — 0.997 Q91ZT1 →
P79750 — 0.997 P79750 →
P20786 — 0.996 P20786 →
P35917 — 0.996 P35917 →